Studies revealed that patients with NASH-driven HCC who received treatment with anti-programmed death receptor-1 or anti-programmed cell death ligand 1 showed lower OS than patients with other etiologies. This evidence concerns the gene CD274 and metabolic dysfunction-associated steatohepatitis.